Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC PILO versus COREG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC PILO versus COREG.
BETOPTIC PILO vs COREG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betoptic Pilo is a combination of betaxolol (a cardioselective beta-1 adrenergic receptor antagonist) and pilocarpine (a muscarinic cholinergic agonist). Betaxolol reduces aqueous humor production by blocking beta-adrenergic receptors in the ciliary epithelium. Pilocarpine increases aqueous humor outflow by contracting the ciliary muscle and opening the trabecular meshwork.
Carvedilol is a nonselective beta-blocker with alpha1-blocking activity. It competitively blocks beta1, beta2, and alpha1 adrenergic receptors, leading to decreased cardiac output, reduced sympathetic tone, and vasodilation. It also has antioxidant and anti-proliferative properties.
One drop of 0.5% betaxolol and 4% pilocarpine combination ophthalmic solution instilled into the affected eye(s) twice daily.
Heart failure: Start 3.125 mg orally twice daily; titrate up to target 25 mg twice daily as tolerated. Hypertension: Start 6.25 mg orally twice daily; increase to max 50 mg twice daily. Post-MI LV dysfunction: Start 3.125-6.25 mg orally twice daily; titrate to target 25 mg twice daily.
None Documented
None Documented
Betaxolol: 16–22 hours (clinical context: allows once-daily dosing for glaucoma). Pilocarpine: 0.5–1.5 hours (rapid elimination, requiring multiple daily dosing).
Terminal elimination half-life is 7-10 hours in most patients, but may be prolonged in severe hepatic impairment (up to 14-18 hours). The half-life is not significantly altered in renal impairment.
Betoptic Pilo (betaxolol and pilocarpine) undergoes both renal and hepatic elimination. Betaxolol is primarily metabolized in the liver (active metabolites) with less than 15% excreted unchanged in urine. Pilocarpine is hydrolyzed in plasma and tissues; its metabolites and a small fraction of unchanged drug are excreted renally. Fecal excretion is negligible.
Renal excretion of unchanged drug and metabolites accounts for approximately 16% of the dose; fecal excretion accounts for about 84% (mainly as metabolites). Less than 2% is excreted unchanged in urine.
Category C
Category C
Beta-Blocker
Beta-Blocker